bendamustine hydrochloride has been researched along with Disease Models, Animal in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Amador, V; Aymerich, M; Campo, E; Colomer, D; Delgado, J; Giró, A; Hanna, BS; Lee-Vergés, E; Lichter, P; López-Guerra, M; Pérez-Galán, P; Rodríguez, ML; Rodríguez, V; Rosich, L; Seiffert, M; Vidal-Crespo, A; Villamor, N; Yazdanparast, H | 1 |
| He, X; Huang, J; Huang, S; Huang, X; Jin, J; Li, C; Li, F; Li, X; Ma, Z; Pan, J; Wang, J; Wang, Y; Xu, Y; Yan, X; Yu, M; Yu, Y; Zhou, Y | 1 |
| Caca, K; Moebius, C; Mossner, J; Niederhagen, M; Schoppmeyer, K; Wiedmann, M; Wittekind, C; Zeh, J | 1 |
4 other study(ies) available for bendamustine hydrochloride and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Topics: Acrylamides; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Tumor Cells, Cultured | 2019 |
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line; Disease Models, Animal; Drug Synergism; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Bendamustine--a new approach to the treatment of advanced hepatocellular carcinoma?
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chimera; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Mice, Nude; Nitrogen Mustard Compounds | 2008 |